Debt Finance TRANSACTIONAL

We guide clients through today's ever-changing debt markets, representing them in a broad variety of debt deals that range from complex financial structures to traditional loan transactions.


WilmerHale's debt finance lawyers provide sophisticated and knowledgeable representation to clients from a wide range of industries, including technology, manufacturing, pharmaceuticals, retail, investment, financial services, real estate and food products. As these clients work to issue, lend and buy debt instruments in a broad spectrum of transactions, we work to find the practical business solutions necessary to get the deals done. With the support of seasoned lawyers from the firm's corporate, securities, life sciences, intellectual property and other practices spanning the United States, Europe and Asia, we are equipped to address the specific needs of clients in even the most complex transactions.

Contacts

Sort By
Sigel, John

John D. Sigel

Partner

+1 617 526 6728 (t)

john.sigel@wilmerhale.com

Ochs, Justin L.

Justin L. Ochs

Vice Chair, Corporate Practice Group

+1 202 663 6303 (t)

justin.ochs@wilmerhale.com

Ochs, Justin L.

Justin L. Ochs

Partner

+1 202 663 6303 (t)

justin.ochs@wilmerhale.com

Robinson, Erika L.

Erika L. Robinson

Partner

+1 202 663 6402 (t)

erika.robinson@wilmerhale.com

Sigel, John

John D. Sigel

Partner

+1 617 526 6728 (t)

john.sigel@wilmerhale.com

Class, Jamie N.

Jamie N. Class

Special Counsel

+1 617 526 6871 (t)

jamie.class@wilmerhale.com

Guadiana_Ellie_lo.jpg

Ellie Guadiana

Senior Associate

+1 213 443 5341 (t)

ellie.guadiana@wilmerhale.com

Tierney, Brandt

Brandt M. Tierney

Senior Associate

+1 202 663 6951 (t)

brandt.tierney@wilmerhale.com

Shin, Mona

Mona Shin

Associate

+1 202 663 6005 (t)

mona.shin@wilmerhale.com

Experience

Our debt finance team represents clients such as Staples, Thermo Fisher Scientific, Cimpress, Hasbro, Dean Foods and Discovery Communications in the following transactions:

  • syndicated senior, second lien and mezzanine-secured debt transactions;
  • acquisition and other leveraged financings;
  • public finance, including placements of senior, subordinated, and exchangeable notes and debentures and the underwriting and sales of various public debt offerings;
  • asset-based financings;
  • letters of credit and other credit support arrangements;
  • operating and capitalized lease facilities and other vendor and trade financings;
  • receivables, securitizations and other specialty finance arrangements, including royalty stream monetization and aircraft financing;
  • project finance transactions;
  • venture and capital call arrangements; and
  • derivatives.

Publications & News

View

October 26, 2017

WilmerHale Reps Franklin Street Properties in $1B Recast of Unsecured Credit Facility

Franklin Street Properties Corporation announced that it has successfully entered into the following transactions: recast of existing unsecured credit facility into $1 billion facility and private placement of $200 million senior unsecured notes.

September 28, 2017

WilmerHale Represents CIRCOR in $855M Acquisition of Colfax’s Fluid Handling Business from Colfax Corp.

CIRCOR International, Inc.—a leading provider of flow control solutions and other highly engineered products for markets including oil & gas, aerospace, power, process and general industrial—announced that it has signed a definitive agreement to acquire Colfax Fluid Handling (CFH) from Colfax Corporation for approximately $855 million including cash, newly issued CIRCOR shares, and the assumption of pension plan liabilities linked to the CFH business.

July 11, 2017

Staples, Inc. Enters Into Definitive Agreement to Be Acquired by Sycamore Partners for $10.25 per Share in Cash, or Approximately $6.9 Billion

Staples, Inc. and Sycamore Partners, a leading private equity firm, announced that they have entered into a merger agreement in which investment funds managed by Sycamore Partners will acquire Staples in a transaction that values Staples at an equity value of approximately $6.9 billion.

July 7, 2017

MKS Instruments Successfully Completes Third Repricing of Secured Term Loan

On July 6, 2017, MKS Instruments, Inc., a global provider of technologies that enable advanced processes and improve productivity, announced the third successful repricing of its existing secured term loan.

July 6, 2017

WilmerHale Represents WEX Inc. in Successful Term Loan Repricing

WEX Inc., a leading provider of corporate payment solutions, announced a successful repricing of the secured term loans under its existing credit facility.

May 26, 2017

WilmerHale Lawyers and Practices Recognized in 2017 Edition of Chambers USA

Chambers and Partners announced its rankings for the 2017 edition of Chambers USA: America's Leading Lawyers for Business, with WilmerHale listed among the nation's best in 50 practice area categories. Chambers also ranked 86 WilmerHale lawyers as leaders in their respective fields.

March 30, 2017

WilmerHale Represents Curis in $45M Debt Transaction with HealthCare Royalty Partners

Curis, Inc., a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, announced a $45 million debt transaction with HealthCare Royalty Partners.

January 11, 2017

ConforMIS Inc. Secures $50M in Debt Financing From Oxford Finance

The WilmerHale deal team representing CFMS includes Partner John Sigel, Special Counsel Jamie Class and Senior Associate Lina Jun.

July 20, 2016

WilmerHale Advises PerkinElmer in €500M Eurobond Offering

PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, announced that it has completed a public offering of €500 million aggregate principal amount of 1.875% Senior Notes due 2026 at an issue price of 99.118% of the principal amount.

July 18, 2016

WilmerHale Advises Intercept Pharmaceuticals in $460M Public Offering

Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, has announced the closing of an underwritten public offering of $460 million aggregate principal amount of 3.25% convertible senior notes due 2023.